{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:22:56Z","timestamp":1792480976012,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12HD043245"],"award-info":[{"award-number":["K12HD043245"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL128349"],"award-info":[{"award-number":["R01 HL128349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24CDA1269277"],"award-info":[{"award-number":["24CDA1269277"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health,United States","award":["R01 HL151345"],"award-info":[{"award-number":["R01 HL151345"]}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84515-9","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T22:55:33Z","timestamp":1735858533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Two-hit mouse model of heart failure with preserved ejection fraction combining diet-induced obesity and renin-mediated hypertension"],"prefix":"10.1038","volume":"15","author":[{"given":"Justin H.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Batmanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiten","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Taing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Callaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Hirenallur-Shanthappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei B.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J. Roth","family":"Flach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"84515_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042220-022745","volume":"73","author":"K Omote","year":"2022","unstructured":"Omote, K., Verbrugge, F. H. & Borlaug, B. A. Heart failure with preserved ejection fraction: mechanisms and treatment strategies. Annu. Rev. Med. 73, 321\u2013337. https:\/\/doi.org\/10.1146\/annurev-med-042220-022745 (2022).","journal-title":"Annu. Rev. Med."},{"key":"84515_CR2","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.122.320257","volume":"130","author":"J Roh","year":"2022","unstructured":"Roh, J., Hill, J. A., Singh, A., Valero-Munoz, M. & Sam, F. Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models. Circ. Res. 130, 1906\u20131925. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.320257 (2022).","journal-title":"Circ. Res."},{"key":"84515_CR3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jacbts.2017.07.013","volume":"2","author":"M Valero-Munoz","year":"2017","unstructured":"Valero-Munoz, M., Backman, W. & Sam, F. Murine models of heart failure with preserved ejection fraction: a fishing expedition. JACC Basic Transl. Sci. 2, 770\u2013789. https:\/\/doi.org\/10.1016\/j.jacbts.2017.07.013 (2017).","journal-title":"JACC Basic Transl. Sci."},{"key":"84515_CR4","doi-asserted-by":"publisher","first-page":"e026071","DOI":"10.1161\/JAHA.122.026071","volume":"11","author":"AN Smith","year":"2022","unstructured":"Smith, A. N. et al. Genomic, proteomic, and metabolic comparisons of small animal models of heart failure with preserved ejection fraction: a tale of mice, rats, and cats. J. Am. Heart Assoc. 11, e026071. https:\/\/doi.org\/10.1161\/JAHA.122.026071 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"84515_CR5","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1093\/eurheartj\/ehab389","volume":"42","author":"C Withaar","year":"2021","unstructured":"Withaar, C., Lam, C. S. P., Schiattarella, G. G., de Boer, R. A. & Meems, L. M. G. Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. Eur. Heart J. 42, 4420\u20134430. https:\/\/doi.org\/10.1093\/eurheartj\/ehab389 (2021).","journal-title":"Eur. Heart J."},{"key":"84515_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","volume":"128","author":"Y Deng","year":"2021","unstructured":"Deng, Y. et al. Targeting mitochondria-inflammation circuit by beta-hydroxybutyrate mitigates HFpEF. Circ. Res. 128, 232\u2013245. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317933 (2021).","journal-title":"Circ. Res."},{"key":"84515_CR7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41467-024-45440-7","volume":"15","author":"S Ranjbarvaziri","year":"2024","unstructured":"Ranjbarvaziri, S. et al. Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice. Nat. Commun. 15, 1352. https:\/\/doi.org\/10.1038\/s41467-024-45440-7 (2024).","journal-title":"Nat. Commun."},{"key":"84515_CR8","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1038\/s41467-024-47327-z","volume":"15","author":"B Li","year":"2024","unstructured":"Li, B. et al. Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1. Nat. Commun. 15, 2953. https:\/\/doi.org\/10.1038\/s41467-024-47327-z (2024).","journal-title":"Nat. Commun."},{"key":"84515_CR9","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00038.2023","author":"D Matsiukevich","year":"2023","unstructured":"Matsiukevich, D. et al. Characterization of a robust mouse model of heart failure with preserved ejection fraction. Am. J. Physiol. Heart Circ. Physiol. https:\/\/doi.org\/10.1152\/ajpheart.00038.2023 (2023).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"84515_CR10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/ehf2.12915","volume":"7","author":"A Schauer","year":"2020","unstructured":"Schauer, A. et al. ZSF1 rat as animal model for HFpEF: development of reduced diastolic function and skeletal muscle dysfunction. ESC Heart Fail. 7, 2123\u20132134. https:\/\/doi.org\/10.1002\/ehf2.12915 (2020).","journal-title":"ESC Heart Fail."},{"key":"84515_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae070","author":"J Mira Hernandez","year":"2024","unstructured":"Mira Hernandez, J. et al. Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic HFpEF model. Cardiovasc. Res. https:\/\/doi.org\/10.1093\/cvr\/cvae070 (2024).","journal-title":"Cardiovasc. Res."},{"key":"84515_CR12","doi-asserted-by":"publisher","first-page":"e027164","DOI":"10.1161\/JAHA.122.027164","volume":"11","author":"B Hegyi","year":"2022","unstructured":"Hegyi, B. et al. Diabetes and excess aldosterone promote heart failure with preserved ejection fraction. J. Am. Heart Assoc. 11, e027164. https:\/\/doi.org\/10.1161\/JAHA.122.027164 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"84515_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCRESAHA.124.324706","volume":"135","author":"C Gao","year":"2024","unstructured":"Gao, C. et al. Glucagon receptor antagonist for heart failure with preserved ejection fraction. Circ. Res. 135, 614\u2013628. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.324706 (2024).","journal-title":"Circ. Res."},{"key":"84515_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella, G. G. et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568, 351\u2013356. https:\/\/doi.org\/10.1038\/s41586-019-1100-z (2019).","journal-title":"Nature"},{"key":"84515_CR15","doi-asserted-by":"publisher","first-page":"e028480","DOI":"10.1161\/JAHA.122.028480","volume":"12","author":"KB LaPenna","year":"2023","unstructured":"LaPenna, K. B. et al. Combination sodium nitrite and hydralazine therapy attenuates heart failure with preserved ejection fraction severity in a 2-Hit murine model. J. Am. Heart Assoc. 12, e028480. https:\/\/doi.org\/10.1161\/JAHA.122.028480 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"84515_CR16","doi-asserted-by":"publisher","first-page":"H443","DOI":"10.1152\/ajpheart.00594.2022","volume":"324","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype. Am. J. Physiol. Heart Circ. Physiol. 324, H443\u2013H460. https:\/\/doi.org\/10.1152\/ajpheart.00594.2022 (2023).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"84515_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","volume":"8","author":"JB Cohen","year":"2020","unstructured":"Cohen, J. B. et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 8, 172\u2013184. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.009 (2020).","journal-title":"JACC Heart Fail."},{"key":"84515_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","volume":"131","author":"SJ Shah","year":"2015","unstructured":"Shah, S. J. et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131, 269\u2013279. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.010637 (2015).","journal-title":"Circulation"},{"key":"84515_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/CIRCULATIONAHA.120.050498","volume":"143","author":"VS Hahn","year":"2021","unstructured":"Hahn, V. S. et al. Myocardial gene expression signatures in human heart failure with preserved ejection fraction. Circulation 143, 120\u2013134. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050498 (2021).","journal-title":"Circulation"},{"key":"84515_CR20","doi-asserted-by":"publisher","first-page":"R467","DOI":"10.1152\/ajpregu.00106.2015","volume":"309","author":"SM Harlan","year":"2015","unstructured":"Harlan, S. M. et al. Viral transduction of renin rapidly establishes persistent hypertension in diverse murine strains. Am. J. Physiol. Regul. Integr. Comp. Physiol. 309, R467\u2013474. https:\/\/doi.org\/10.1152\/ajpregu.00106.2015 (2015).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"84515_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/CIRCULATIONAHA.122.061828","volume":"147","author":"S Sarma","year":"2023","unstructured":"Sarma, S. et al. Challenging the hemodynamic hypothesis in heart failure with preserved ejection fraction: is exercise capacity limited by elevated pulmonary capillary wedge pressure? Circulation 147, 378\u2013387. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061828 (2023).","journal-title":"Circulation"},{"key":"84515_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jchf.2018.03.003","volume":"6","author":"YNV Reddy","year":"2018","unstructured":"Reddy, Y. N. V., Olson, T. P., Obokata, M., Melenovsky, V. & Borlaug, B. A. Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. JACC Heart Fail. 6, 665\u2013675. https:\/\/doi.org\/10.1016\/j.jchf.2018.03.003 (2018).","journal-title":"JACC Heart Fail."},{"key":"84515_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jchf.2019.01.004","volume":"7","author":"AL Beale","year":"2019","unstructured":"Beale, A. L. et al. Sex differences in heart failure with preserved ejection fraction pathophysiology: a detailed invasive hemodynamic and echocardiographic analysis. JACC Heart Fail. 7, 239\u2013249. https:\/\/doi.org\/10.1016\/j.jchf.2019.01.004 (2019).","journal-title":"JACC Heart Fail."},{"key":"84515_CR24","doi-asserted-by":"publisher","first-page":"107795","DOI":"10.1016\/j.jdiacomp.2020.107795","volume":"35","author":"I Casimiro","year":"2021","unstructured":"Casimiro, I., Stull, N. D., Tersey, S. A. & Mirmira, R. G. Phenotypic sexual dimorphism in response to dietary fat manipulation in C57BL\/6J mice. J. Diabetes Complications 35, 107795. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107795 (2021).","journal-title":"J. Diabetes Complications"},{"key":"84515_CR25","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41366-022-01174-4","volume":"46","author":"J Oraha","year":"2022","unstructured":"Oraha, J., Enriquez, R. F., Herzog, H. & Lee, N. J. Sex-specific changes in metabolism during the transition from chow to high-fat diet feeding are abolished in response to dieting in C57BL\/6J mice. Int. J. Obes. (Lond.) 46, 1749\u20131758. https:\/\/doi.org\/10.1038\/s41366-022-01174-4 (2022).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"84515_CR26","doi-asserted-by":"publisher","first-page":"e00708","DOI":"10.1002\/brb3.708","volume":"7","author":"RR Gelineau","year":"2017","unstructured":"Gelineau, R. R. et al. The behavioral and physiological effects of high-fat diet and alcohol consumption: sex differences in C57BL6\/J mice. Brain Behav. 7, e00708. https:\/\/doi.org\/10.1002\/brb3.708 (2017).","journal-title":"Brain Behav."},{"key":"84515_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1161\/CIRCULATIONAHA.122.060348","volume":"146","author":"SD Anker","year":"2022","unstructured":"Anker, S. D., Usman, M. S. & Butler, J. SGLT2 inhibitors: from antihyperglycemic agents to all-around heart failure therapy. Circulation 146, 299\u2013302. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060348 (2022).","journal-title":"Circulation"},{"key":"84515_CR28","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1313731 (2014).","journal-title":"N. Engl. J. Med."},{"key":"84515_CR29","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D. et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655 (2019).","journal-title":"N. Engl. J. Med."},{"key":"84515_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf, S. et al. Effects of Candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362, 777\u2013781. https:\/\/doi.org\/10.1016\/S0140-6736(03)14285-7 (2003).","journal-title":"Lancet"},{"key":"84515_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.yjmcc.2017.10.006","volume":"114","author":"M Schnelle","year":"2018","unstructured":"Schnelle, M. et al. Echocardiographic evaluation of diastolic function in mouse models of heart disease. J. Mol. Cell. Cardiol. 114, 20\u201328. https:\/\/doi.org\/10.1016\/j.yjmcc.2017.10.006 (2018).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"84515_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2024.10.001","volume":"197","author":"DA Kass","year":"2024","unstructured":"Kass, D. A. Assessing and interpreting diastolic function in animal models of heart disease. J. Mol. Cell. Cardiol. 197, 1\u20134. https:\/\/doi.org\/10.1016\/j.yjmcc.2024.10.001 (2024).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"84515_CR33","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1161\/CIRCULATIONAHA.119.042267","volume":"140","author":"D Tong","year":"2019","unstructured":"Tong, D. et al. Female sex is protective in a preclinical model of heart failure with preserved ejection fraction. Circulation 140, 1769\u20131771. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042267 (2019).","journal-title":"Circulation"},{"key":"84515_CR34","doi-asserted-by":"publisher","first-page":"966968","DOI":"10.3389\/fcvm.2022.966968","volume":"9","author":"M Valero-Munoz","year":"2022","unstructured":"Valero-Munoz, M. et al. Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF). Front. Cardiovasc. Med. 9, 966968. https:\/\/doi.org\/10.3389\/fcvm.2022.966968 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"84515_CR35","doi-asserted-by":"publisher","first-page":"16042","DOI":"10.1038\/s41598-017-16201-y","volume":"7","author":"FA van Nieuwenhoven","year":"2017","unstructured":"van Nieuwenhoven, F. A. et al. Cartilage intermediate layer protein 1 (CILP1): a novel mediator of cardiac extracellular matrix remodelling. Sci. Rep. 7, 16042. https:\/\/doi.org\/10.1038\/s41598-017-16201-y (2017).","journal-title":"Sci. Rep."},{"key":"84515_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jacbts.2020.01.016","volume":"5","author":"S Park","year":"2020","unstructured":"Park, S., Ranjbarvaziri, S., Zhao, P. & Ardehali, R. Cardiac Fibrosis is associated with decreased circulating levels of full-length CILP in heart failure. JACC Basic Transl. Sci. 5, 432\u2013443. https:\/\/doi.org\/10.1016\/j.jacbts.2020.01.016 (2020).","journal-title":"JACC Basic Transl. Sci."},{"key":"84515_CR37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacbts.2020.03.013","volume":"5","author":"S Gross","year":"2020","unstructured":"Gross, S. & Thum, T. TGF-beta inhibitor CILP as a novel biomarker for cardiac fibrosis. JACC Basic Transl. Sci. 5, 444\u2013446. https:\/\/doi.org\/10.1016\/j.jacbts.2020.03.013 (2020).","journal-title":"JACC Basic Transl. Sci."},{"key":"84515_CR38","doi-asserted-by":"publisher","first-page":"19757","DOI":"10.1038\/s41598-021-99032-2","volume":"11","author":"KB Rypdal","year":"2021","unstructured":"Rypdal, K. B. et al. The extracellular matrix glycoprotein ADAMTSL2 is increased in heart failure and inhibits TGFbeta signalling in cardiac fibroblasts. Sci. Rep. 11, 19757. https:\/\/doi.org\/10.1038\/s41598-021-99032-2 (2021).","journal-title":"Sci. Rep."},{"key":"84515_CR39","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","volume":"147","author":"VS Hahn","year":"2023","unstructured":"Hahn, V. S. et al. Myocardial metabolomics of human heart failure with preserved ejection fraction. Circulation 147, 1147\u20131161. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061846 (2023).","journal-title":"Circulation"},{"key":"84515_CR40","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038 (2021).","journal-title":"N. Engl. J. Med."},{"key":"84515_CR41","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286 (2022).","journal-title":"N. Engl. J. Med."},{"key":"84515_CR42","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","volume":"117","author":"C Withaar","year":"2021","unstructured":"Withaar, C. et al. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovasc. Res. 117, 2108\u20132124. https:\/\/doi.org\/10.1093\/cvr\/cvaa256 (2021).","journal-title":"Cardiovasc. Res."},{"key":"84515_CR43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/FJC.0000000000001474","volume":"82","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Dapagliflozin attenuates heart failure with preserved ejection fraction remodeling and dysfunction by elevating beta-hydroxybutyrate-activated citrate synthase. J. Cardiovasc. Pharmacol. 82, 375\u2013388. https:\/\/doi.org\/10.1097\/FJC.0000000000001474 (2023).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"84515_CR44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073\u20131080. https:\/\/doi.org\/10.1038\/mt.2008.76 (2008).","journal-title":"Mol. Ther."},{"key":"84515_CR45","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.29.591665","author":"JH Berger","year":"2024","unstructured":"Berger, J. H. et al. Sodium-glucose co-transporter 2 inhibitors Act independently of SGLT2 to confer benefit for heart failure with reduced ejection fraction in mice. bioRxiv. https:\/\/doi.org\/10.1101\/2024.04.29.591665 (2024).","journal-title":"bioRxiv"},{"key":"84515_CR46","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1161\/CIRCRESAHA.119.316100","volume":"126","author":"T Sakamoto","year":"2020","unstructured":"Sakamoto, T. et al. A critical role for estrogen-related receptor signaling in cardiac maturation. Circ. Res. 126, 1685\u20131702. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.316100 (2020).","journal-title":"Circ. Res."},{"key":"84515_CR47","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/s41467-022-29733-3","volume":"13","author":"T Sakamoto","year":"2022","unstructured":"Sakamoto, T. et al. The nuclear receptor ERR cooperates with the cardiogenic factor GATA4 to orchestrate cardiomyocyte maturation. Nat. Commun. 13, 1991. https:\/\/doi.org\/10.1038\/s41467-022-29733-3 (2022).","journal-title":"Nat. Commun."},{"key":"84515_CR48","doi-asserted-by":"publisher","unstructured":"Yamamoto, T. et al. RIP140 deficiency enhances cardiac fuel metabolism and protects mice from heart failure. J. Clin. Investig. 133. https:\/\/doi.org\/10.1172\/JCI162309 (2023).","DOI":"10.1172\/JCI162309"},{"key":"84515_CR49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419. https:\/\/doi.org\/10.1038\/nmeth.4197 (2017).","journal-title":"Nat. Methods"},{"key":"84515_CR50","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."},{"key":"84515_CR51","doi-asserted-by":"publisher","first-page":"W207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg, L. et al. G:profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 51, W207\u2013W212. https:\/\/doi.org\/10.1093\/nar\/gkad347 (2023).","journal-title":"Nucleic Acids Res."},{"key":"84515_CR52","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592. https:\/\/doi.org\/10.1093\/nar\/gkac963 (2023).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84515-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84515-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84515-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:05:03Z","timestamp":1735949103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84515-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84515"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84515-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.06.597821","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DPK is a consultant for Pfizer Inc. YS, KT, XC, MM, RK, DH-S, RM, BBZ, RJRF are employees of Pfizer Inc. or were employees at the time the research was conducted. Multiple Pfizer authors own Pfizer stock. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"422"}}